Idelalisib + Nab-paclitaxel + mFOLFOX6
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Previously Untreated Pancreatic Ductal Adenocarcinoma
Conditions
Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Trial Timeline
Jul 30, 2015 → Apr 27, 2016
NCT ID
NCT02468557About Idelalisib + Nab-paclitaxel + mFOLFOX6
Idelalisib + Nab-paclitaxel + mFOLFOX6 is a phase 1 stage product being developed by Gilead Sciences for Previously Untreated Pancreatic Ductal Adenocarcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02468557. Target conditions include Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02468557 | Phase 1 | Terminated |
Competing Products
8 competing products in Previously Untreated Pancreatic Ductal Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811 | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim | AstraZeneca | Phase 2 | 52 |
| AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin | AstraZeneca | Phase 2 | 52 |
| UFOX + Cetuximab + FOLFOX4 + Cetuximab | Merck | Phase 2 | 52 |
| Bosutinib | Pfizer | Approved | 84 |
| CRS-207 + CRS-207 + nivolumab + GVAX + CY | Bristol Myers Squibb | Phase 2 | 51 |
| Lenalidomide + Dexamethasone + Elotuzumab | Bristol Myers Squibb | Phase 3 | 76 |
| Oxaliplatin | Sanofi | Phase 2 | 51 |